Sean G Rudd

List of Publications by Year in Descending Order

25 papers	742 citations	14 h-index	27 g-index
33 ext. papers	994 ext. citations	9 avg, IF	3.7 L-index

#	Paper	IF	Citations
25	The prognostic and clinicopathological significance of desmoglein 2 in human cancers: a systematic review and meta-analysis.. *PeerJ*, **2022**, 10, e13141	3.1	1
24	NUDT15-mediated hydrolysis limits the efficacy of anti-HCMV drug ganciclovir. *Cell Chemical Biology*, **2021**,	8.2	1
23	Crystal structures of NUDT15 variants enabled by a potent inhibitor reveal the structural basis for thiopurine sensitivity. *Journal of Biological Chemistry*, **2021**, 296, 100568	5.4	2
22	Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells. *Cell Death and Disease*, **2021**, 12, 709	9.8	2
21	Drug synergy scoring using minimal dose response matrices. *BMC Research Notes*, **2021**, 14, 27	2.3	1
20	Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy. *EMBO Molecular Medicine*, **2020**, 12, e10419	12	14
19	Cell Cycle Profiling Reveals Protein Oscillation, Phosphorylation, and Localization Dynamics. *Molecular and Cellular Proteomics*, **2020**, 19, 608-623	7.6	9
18	MTH1 Inhibitor TH588 Disturbs Mitotic Progression and Induces Mitosis-Dependent Accumulation of Genomic 8-oxodG. *Cancer Research*, **2020**, 80, 3530-3541	10.1	7
17	Development of a chemical probe against NUDT15. *Nature Chemical Biology*, **2020**, 16, 1120-1128	11.7	5
16	Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells. *Nature Communications*, **2018**, 9, 250	17.4	28
15	Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism. *Cancers*, **2018**, 10,	6.6	51
14	Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens. *Blood Cancer Journal*, **2018**, 8, 98	7	13
13	Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies. *Nature Medicine*, **2017**, 23, 256-263	50.5	69
12	SAMHD1 is a barrier to antimetabolite-based cancer therapies. *Molecular and Cellular Oncology*, **2017**, 4, e1287554	1.2	8
11	SAMHD1 protects cancer cells from various nucleoside-based antimetabolites. *Cell Cycle*, **2017**, 16, 1029-1038	4.4	35
10	With me or against me: Tumor suppressor and drug resistance activities of SAMHD1. *Experimental Hematology*, **2017**, 52, 32-39	3.1	23
9	Validation and development of MTH1 inhibitors for treatment of cancer. *Annals of Oncology*, **2016**, 27, 2275-2283	10.3	77

List of Publications

8	Pathways controlling dNTP pools to maintain genome stability. *DNA Repair*, **2016**, 44, 193-204	4.3	39
7	hMYH and hMTH1 cooperate for survival in mismatch repair defective T-cell acute lymphoblastic leukemia. *Oncogenesis*, **2016**, 5, e275	6.6	14
6	Human PrimPol is a highly error-prone polymerase regulated by single-stranded DNA binding proteins. *Nucleic Acids Research*, **2015**, 43, 1056-68	20.1	63
5	PrimPol-A new polymerase on the block. *Molecular and Cellular Oncology*, **2014**, 1, e960754	1.2	26
4	PPL2 translesion polymerase is essential for the completion of chromosomal DNA replication in the African trypanosome. *Molecular Cell*, **2013**, 52, 554-65	17.6	44
3	PrimPol bypasses UV photoproducts during eukaryotic chromosomal DNA replication. *Molecular Cell*, **2013**, 52, 566-73	17.6	175
2	WT1 and its transcriptional cofactor BASP1 redirect the differentiation pathway of an established blood cell line. *Biochemical Journal*, **2011**, 435, 113-25	3.8	30
1	MTH1 promotes mitotic progression to avoid oxidative DNA damage in cancer cells		3